Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,356 recalls, newest first

Class II · Moderate risk

Ethosuximide Oral Solution USP 250 mg/5 mL

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0670-16 D-0723-2021
Class II · Moderate risk

Nystatin Oral Suspension

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Terminated cGMP deviation PAI Holdings, LLC. dba Pharmaceutical Associates Inc NDC 0121-0868-16 D-0721-2021
Class II · Moderate risk

Zyprexa Intramuscular

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

Terminated cGMP deviation Eli Lilly & Company NDC 0002-7597-01 D-0720-2021
Class II · Moderate risk

Oxygen

cGMP deviations

Terminated cGMP deviation Grace Healthcare Medical, Inc D-0355-2021
Class II · Moderate risk

Durisan Antimicrobial Solutions

CGMP Deviations: lots recalled due to CGMP deviations because they were manufactured under the same conditions as product lots found to be contaminated.

Terminated cGMP deviation Sanit Technologies, LLC dba Durisan D-0659-2021
Class II · Moderate risk

Durisan Antimicrobial Solutions

CGMP Deviations: lots recalled due to CGMP deviations because they were manufactured under the same conditions as product lots found to be contaminated.

Terminated cGMP deviation Sanit Technologies, LLC dba Durisan D-0658-2021
Class II · Moderate risk

Nortriptyline HCL capsules

cGMP deviations: The quantity of active ingredient used for the product lot was inadvertently taken from an ingredient lot from an alternate supplier before that specific lot was formally qualified for use by the manufacturing site.

Terminated cGMP deviation Direct Rx D-0300-2021

Recalls by year